1. Home
  2. YETI vs IRON Comparison

YETI vs IRON Comparison

Compare YETI & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo YETI Holdings Inc.

YETI

YETI Holdings Inc.

HOLD

Current Price

$46.42

Market Cap

3.3B

ML Signal

HOLD

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

HOLD

Current Price

$78.36

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YETI
IRON
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.0B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
YETI
IRON
Price
$46.42
$78.36
Analyst Decision
Buy
Strong Buy
Analyst Count
13
13
Target Price
$39.33
$108.85
AVG Volume (30 Days)
1.9M
644.9K
Earning Date
02-12-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.93
N/A
Revenue
$1,831,326,000.00
N/A
Revenue This Year
$4.00
N/A
Revenue Next Year
$5.47
N/A
P/E Ratio
$23.29
N/A
Revenue Growth
1.56
N/A
52 Week Low
$26.61
$30.82
52 Week High
$46.28
$99.50

Technical Indicators

Market Signals
Indicator
YETI
IRON
Relative Strength Index (RSI) 67.10 35.93
Support Level $43.82 $76.24
Resistance Level $46.08 $80.32
Average True Range (ATR) 1.17 3.98
MACD -0.16 -0.97
Stochastic Oscillator 77.59 33.81

Price Performance

Historical Comparison
YETI
IRON

About YETI YETI Holdings Inc.

YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Share on Social Networks: